Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Short-term Investments (2019 - 2026)

Kymera Therapeutics has reported Short-term Investments over the past 8 years, most recently at $506.8 million for Q1 2026.

  • Quarterly Short-term Investments rose 35.81% to $506.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $506.8 million through Mar 2026, up 35.81% year-over-year, with the annual reading at $491.3 million for FY2025, 33.32% up from the prior year.
  • Short-term Investments was $506.8 million for Q1 2026 at Kymera Therapeutics, up from $491.3 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $506.8 million in Q1 2026 and troughed at $264.9 million in Q4 2023.
  • The 5-year median for Short-term Investments is $368.5 million (2024), against an average of $376.0 million.
  • Year-over-year, Short-term Investments soared 58.7% in 2024 and then decreased 25.48% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $338.8 million in 2022, then dropped by 21.8% to $264.9 million in 2023, then skyrocketed by 39.1% to $368.5 million in 2024, then surged by 33.32% to $491.3 million in 2025, then increased by 3.17% to $506.8 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Short-term Investments are $506.8 million (Q1 2026), $491.3 million (Q4 2025), and $392.7 million (Q3 2025).